nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—Methotrexate—lymphatic system cancer	0.422	1	CrCtD
Pralatrexate—SLC19A1—Methotrexate—lymphatic system cancer	0.113	0.426	CbGbCtD
Pralatrexate—FPGS—Methotrexate—lymphatic system cancer	0.0819	0.308	CbGbCtD
Pralatrexate—Raltitrexed—Methotrexate—lymphatic system cancer	0.0559	0.2	CrCrCtD
Pralatrexate—Tetrahydrofolic acid—Methotrexate—lymphatic system cancer	0.0559	0.2	CrCrCtD
Pralatrexate—Pemetrexed—Methotrexate—lymphatic system cancer	0.0559	0.2	CrCrCtD
Pralatrexate—Leucovorin—Methotrexate—lymphatic system cancer	0.0559	0.2	CrCrCtD
Pralatrexate—Folic Acid—Methotrexate—lymphatic system cancer	0.0559	0.2	CrCrCtD
Pralatrexate—DHFR—Methotrexate—lymphatic system cancer	0.0416	0.157	CbGbCtD
Pralatrexate—TYMS—Methotrexate—lymphatic system cancer	0.029	0.109	CbGbCtD
Pralatrexate—Tumour lysis syndrome—Fludarabine—lymphatic system cancer	0.00198	0.0634	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Vincristine—lymphatic system cancer	0.00121	0.0387	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Mitoxantrone—lymphatic system cancer	0.00118	0.0377	CcSEcCtD
Pralatrexate—Tumour lysis syndrome—Methotrexate—lymphatic system cancer	0.000588	0.0188	CcSEcCtD
Pralatrexate—Sepsis—Teniposide—lymphatic system cancer	0.000544	0.0174	CcSEcCtD
Pralatrexate—Pancytopenia—Mechlorethamine—lymphatic system cancer	0.000507	0.0162	CcSEcCtD
Pralatrexate—TYMS—Podofilox—Teniposide—lymphatic system cancer	0.000502	0.4	CbGdCrCtD
Pralatrexate—Liver function test abnormal—Teniposide—lymphatic system cancer	0.00042	0.0134	CcSEcCtD
Pralatrexate—Pancytopenia—Teniposide—lymphatic system cancer	0.000374	0.0119	CcSEcCtD
Pralatrexate—Dehydration—Fludarabine—lymphatic system cancer	0.000372	0.0119	CcSEcCtD
Pralatrexate—Liver function test abnormal—Fludarabine—lymphatic system cancer	0.000369	0.0118	CcSEcCtD
Pralatrexate—Neutropenia—Teniposide—lymphatic system cancer	0.000368	0.0118	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Fludarabine—lymphatic system cancer	0.00036	0.0115	CcSEcCtD
Pralatrexate—Leukopenia—Mechlorethamine—lymphatic system cancer	0.000333	0.0106	CcSEcCtD
Pralatrexate—Pancytopenia—Fludarabine—lymphatic system cancer	0.000328	0.0105	CcSEcCtD
Pralatrexate—Neutropenia—Fludarabine—lymphatic system cancer	0.000323	0.0103	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.000321	0.0103	CcSEcCtD
Pralatrexate—Sepsis—Carmustine—lymphatic system cancer	0.000306	0.00978	CcSEcCtD
Pralatrexate—TYMS—Vinorelbine—Vincristine—lymphatic system cancer	0.000299	0.238	CbGdCrCtD
Pralatrexate—Thrombocytopenia—Mechlorethamine—lymphatic system cancer	0.000297	0.00949	CcSEcCtD
Pralatrexate—Epistaxis—Fludarabine—lymphatic system cancer	0.000291	0.00929	CcSEcCtD
Pralatrexate—Anorexia—Mechlorethamine—lymphatic system cancer	0.000289	0.00924	CcSEcCtD
Pralatrexate—Sepsis—Mitoxantrone—lymphatic system cancer	0.000284	0.00909	CcSEcCtD
Pralatrexate—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.000264	0.00843	CcSEcCtD
Pralatrexate—Anaemia—Teniposide—lymphatic system cancer	0.000253	0.00809	CcSEcCtD
Pralatrexate—Leukopenia—Teniposide—lymphatic system cancer	0.000245	0.00784	CcSEcCtD
Pralatrexate—Pain in extremity—Vincristine—lymphatic system cancer	0.000244	0.00781	CcSEcCtD
Pralatrexate—Pancytopenia—Bleomycin—lymphatic system cancer	0.000241	0.00769	CcSEcCtD
Pralatrexate—Liver function test abnormal—Carmustine—lymphatic system cancer	0.000236	0.00755	CcSEcCtD
Pralatrexate—Hypokalaemia—Carmustine—lymphatic system cancer	0.000233	0.00744	CcSEcCtD
Pralatrexate—Dehydration—Vincristine—lymphatic system cancer	0.000227	0.00726	CcSEcCtD
Pralatrexate—Oedema—Teniposide—lymphatic system cancer	0.000224	0.00715	CcSEcCtD
Pralatrexate—Anaemia—Fludarabine—lymphatic system cancer	0.000223	0.00711	CcSEcCtD
Pralatrexate—Dehydration—Mitoxantrone—lymphatic system cancer	0.000221	0.00707	CcSEcCtD
Pralatrexate—Thrombocytopenia—Teniposide—lymphatic system cancer	0.000219	0.007	CcSEcCtD
Pralatrexate—Tachycardia—Teniposide—lymphatic system cancer	0.000218	0.00697	CcSEcCtD
Pralatrexate—Hypokalaemia—Mitoxantrone—lymphatic system cancer	0.000217	0.00692	CcSEcCtD
Pralatrexate—Leukopenia—Fludarabine—lymphatic system cancer	0.000216	0.00689	CcSEcCtD
Pralatrexate—Pruritus—Mechlorethamine—lymphatic system cancer	0.000215	0.00686	CcSEcCtD
Pralatrexate—Anorexia—Teniposide—lymphatic system cancer	0.000213	0.00681	CcSEcCtD
Pralatrexate—Cough—Fludarabine—lymphatic system cancer	0.00021	0.00672	CcSEcCtD
Pralatrexate—Pancytopenia—Carmustine—lymphatic system cancer	0.00021	0.00671	CcSEcCtD
Pralatrexate—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000208	0.00663	CcSEcCtD
Pralatrexate—Neutropenia—Carmustine—lymphatic system cancer	0.000207	0.00661	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vincristine—lymphatic system cancer	0.000205	0.164	CbGdCrCtD
Pralatrexate—Pancytopenia—Vincristine—lymphatic system cancer	0.000201	0.00641	CcSEcCtD
Pralatrexate—Dyspnoea—Teniposide—lymphatic system cancer	0.000199	0.00637	CcSEcCtD
Pralatrexate—Neutropenia—Vincristine—lymphatic system cancer	0.000197	0.00631	CcSEcCtD
Pralatrexate—Oedema—Fludarabine—lymphatic system cancer	0.000197	0.00628	CcSEcCtD
Pralatrexate—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.000195	0.00624	CcSEcCtD
Pralatrexate—Decreased appetite—Teniposide—lymphatic system cancer	0.000194	0.00621	CcSEcCtD
Pralatrexate—Vomiting—Mechlorethamine—lymphatic system cancer	0.000193	0.00616	CcSEcCtD
Pralatrexate—Thrombocytopenia—Fludarabine—lymphatic system cancer	0.000192	0.00615	CcSEcCtD
Pralatrexate—Neutropenia—Mitoxantrone—lymphatic system cancer	0.000192	0.00614	CcSEcCtD
Pralatrexate—Rash—Mechlorethamine—lymphatic system cancer	0.000191	0.00611	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.000191	0.00611	CcSEcCtD
Pralatrexate—Dermatitis—Mechlorethamine—lymphatic system cancer	0.000191	0.00611	CcSEcCtD
Pralatrexate—Anorexia—Fludarabine—lymphatic system cancer	0.000187	0.00599	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.000183	0.00584	CcSEcCtD
Pralatrexate—Nausea—Mechlorethamine—lymphatic system cancer	0.00018	0.00576	CcSEcCtD
Pralatrexate—Abdominal pain—Teniposide—lymphatic system cancer	0.000177	0.00565	CcSEcCtD
Pralatrexate—Body temperature increased—Teniposide—lymphatic system cancer	0.000177	0.00565	CcSEcCtD
Pralatrexate—Dyspnoea—Fludarabine—lymphatic system cancer	0.000175	0.0056	CcSEcCtD
Pralatrexate—Decreased appetite—Fludarabine—lymphatic system cancer	0.000171	0.00546	CcSEcCtD
Pralatrexate—Fatigue—Fludarabine—lymphatic system cancer	0.000169	0.00541	CcSEcCtD
Pralatrexate—Constipation—Fludarabine—lymphatic system cancer	0.000168	0.00537	CcSEcCtD
Pralatrexate—Anaemia—Bleomycin—lymphatic system cancer	0.000163	0.00522	CcSEcCtD
Pralatrexate—Asthenia—Teniposide—lymphatic system cancer	0.00016	0.00513	CcSEcCtD
Pralatrexate—Pruritus—Teniposide—lymphatic system cancer	0.000158	0.00506	CcSEcCtD
Pralatrexate—Leukopenia—Bleomycin—lymphatic system cancer	0.000158	0.00505	CcSEcCtD
Pralatrexate—Body temperature increased—Fludarabine—lymphatic system cancer	0.000155	0.00496	CcSEcCtD
Pralatrexate—Cough—Bleomycin—lymphatic system cancer	0.000154	0.00492	CcSEcCtD
Pralatrexate—Diarrhoea—Teniposide—lymphatic system cancer	0.000153	0.00489	CcSEcCtD
Pralatrexate—Back pain—Carmustine—lymphatic system cancer	0.000149	0.00476	CcSEcCtD
Pralatrexate—Oedema—Bleomycin—lymphatic system cancer	0.000144	0.0046	CcSEcCtD
Pralatrexate—Anaemia—Carmustine—lymphatic system cancer	0.000142	0.00455	CcSEcCtD
Pralatrexate—Back pain—Vincristine—lymphatic system cancer	0.000142	0.00455	CcSEcCtD
Pralatrexate—Vomiting—Teniposide—lymphatic system cancer	0.000142	0.00454	CcSEcCtD
Pralatrexate—Sepsis—Methotrexate—lymphatic system cancer	0.000142	0.00453	CcSEcCtD
Pralatrexate—Thrombocytopenia—Bleomycin—lymphatic system cancer	0.000141	0.00451	CcSEcCtD
Pralatrexate—Asthenia—Fludarabine—lymphatic system cancer	0.000141	0.00451	CcSEcCtD
Pralatrexate—Rash—Teniposide—lymphatic system cancer	0.000141	0.00451	CcSEcCtD
Pralatrexate—Dermatitis—Teniposide—lymphatic system cancer	0.000141	0.0045	CcSEcCtD
Pralatrexate—Pruritus—Fludarabine—lymphatic system cancer	0.000139	0.00444	CcSEcCtD
Pralatrexate—Back pain—Mitoxantrone—lymphatic system cancer	0.000139	0.00443	CcSEcCtD
Pralatrexate—Leukopenia—Carmustine—lymphatic system cancer	0.000138	0.00441	CcSEcCtD
Pralatrexate—Anorexia—Bleomycin—lymphatic system cancer	0.000137	0.00439	CcSEcCtD
Pralatrexate—Anaemia—Vincristine—lymphatic system cancer	0.000136	0.00435	CcSEcCtD
Pralatrexate—Diarrhoea—Fludarabine—lymphatic system cancer	0.000135	0.0043	CcSEcCtD
Pralatrexate—Nausea—Teniposide—lymphatic system cancer	0.000133	0.00424	CcSEcCtD
Pralatrexate—Anaemia—Mitoxantrone—lymphatic system cancer	0.000132	0.00423	CcSEcCtD
Pralatrexate—Leukopenia—Vincristine—lymphatic system cancer	0.000132	0.00421	CcSEcCtD
Pralatrexate—Dyspnoea—Bleomycin—lymphatic system cancer	0.000128	0.00411	CcSEcCtD
Pralatrexate—Leukopenia—Mitoxantrone—lymphatic system cancer	0.000128	0.0041	CcSEcCtD
Pralatrexate—TYMS—Azacitidine—Fludarabine—lymphatic system cancer	0.000127	0.102	CbGdCrCtD
Pralatrexate—Oedema—Carmustine—lymphatic system cancer	0.000126	0.00402	CcSEcCtD
Pralatrexate—Decreased appetite—Bleomycin—lymphatic system cancer	0.000125	0.004	CcSEcCtD
Pralatrexate—Cough—Mitoxantrone—lymphatic system cancer	0.000125	0.004	CcSEcCtD
Pralatrexate—Vomiting—Fludarabine—lymphatic system cancer	0.000125	0.00399	CcSEcCtD
Pralatrexate—Rash—Fludarabine—lymphatic system cancer	0.000124	0.00396	CcSEcCtD
Pralatrexate—Dermatitis—Fludarabine—lymphatic system cancer	0.000124	0.00396	CcSEcCtD
Pralatrexate—Thrombocytopenia—Carmustine—lymphatic system cancer	0.000123	0.00394	CcSEcCtD
Pralatrexate—Tachycardia—Carmustine—lymphatic system cancer	0.000123	0.00392	CcSEcCtD
Pralatrexate—TYMS—Azacitidine—Cytarabine—lymphatic system cancer	0.00012	0.096	CbGdCrCtD
Pralatrexate—Oedema—Vincristine—lymphatic system cancer	0.00012	0.00384	CcSEcCtD
Pralatrexate—Anorexia—Carmustine—lymphatic system cancer	0.00012	0.00383	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vincristine—lymphatic system cancer	0.000118	0.00376	CcSEcCtD
Pralatrexate—Oedema—Mitoxantrone—lymphatic system cancer	0.000117	0.00374	CcSEcCtD
Pralatrexate—Nausea—Fludarabine—lymphatic system cancer	0.000117	0.00373	CcSEcCtD
Pralatrexate—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	0.000115	0.00366	CcSEcCtD
Pralatrexate—Anorexia—Vincristine—lymphatic system cancer	0.000114	0.00366	CcSEcCtD
Pralatrexate—Tachycardia—Mitoxantrone—lymphatic system cancer	0.000114	0.00365	CcSEcCtD
Pralatrexate—Body temperature increased—Bleomycin—lymphatic system cancer	0.000114	0.00364	CcSEcCtD
Pralatrexate—Dyspnoea—Carmustine—lymphatic system cancer	0.000112	0.00358	CcSEcCtD
Pralatrexate—Anorexia—Mitoxantrone—lymphatic system cancer	0.000111	0.00356	CcSEcCtD
Pralatrexate—Liver function test abnormal—Methotrexate—lymphatic system cancer	0.000109	0.0035	CcSEcCtD
Pralatrexate—Decreased appetite—Carmustine—lymphatic system cancer	0.000109	0.00349	CcSEcCtD
Pralatrexate—Constipation—Carmustine—lymphatic system cancer	0.000108	0.00344	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000107	0.00341	CcSEcCtD
Pralatrexate—Decreased appetite—Vincristine—lymphatic system cancer	0.000104	0.00334	CcSEcCtD
Pralatrexate—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.000104	0.00333	CcSEcCtD
Pralatrexate—Fatigue—Vincristine—lymphatic system cancer	0.000104	0.00331	CcSEcCtD
Pralatrexate—Asthenia—Bleomycin—lymphatic system cancer	0.000103	0.0033	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000103	0.00329	CcSEcCtD
Pralatrexate—Constipation—Vincristine—lymphatic system cancer	0.000103	0.00328	CcSEcCtD
Pralatrexate—Pruritus—Bleomycin—lymphatic system cancer	0.000102	0.00326	CcSEcCtD
Pralatrexate—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000102	0.00325	CcSEcCtD
Pralatrexate—Fatigue—Mitoxantrone—lymphatic system cancer	0.000101	0.00322	CcSEcCtD
Pralatrexate—Constipation—Mitoxantrone—lymphatic system cancer	0.0001	0.0032	CcSEcCtD
Pralatrexate—Abdominal pain—Carmustine—lymphatic system cancer	9.95e-05	0.00318	CcSEcCtD
Pralatrexate—Body temperature increased—Carmustine—lymphatic system cancer	9.95e-05	0.00318	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vincristine—lymphatic system cancer	9.82e-05	0.00314	CcSEcCtD
Pralatrexate—Pancytopenia—Methotrexate—lymphatic system cancer	9.73e-05	0.00311	CcSEcCtD
Pralatrexate—Neutropenia—Methotrexate—lymphatic system cancer	9.58e-05	0.00306	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	9.56e-05	0.00306	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	9.52e-05	0.00304	CcSEcCtD
Pralatrexate—Abdominal pain—Vincristine—lymphatic system cancer	9.49e-05	0.00303	CcSEcCtD
Pralatrexate—Body temperature increased—Vincristine—lymphatic system cancer	9.49e-05	0.00303	CcSEcCtD
Pralatrexate—Abdominal pain—Mitoxantrone—lymphatic system cancer	9.25e-05	0.00295	CcSEcCtD
Pralatrexate—Body temperature increased—Mitoxantrone—lymphatic system cancer	9.25e-05	0.00295	CcSEcCtD
Pralatrexate—Vomiting—Bleomycin—lymphatic system cancer	9.16e-05	0.00293	CcSEcCtD
Pralatrexate—Rash—Bleomycin—lymphatic system cancer	9.09e-05	0.0029	CcSEcCtD
Pralatrexate—Dermatitis—Bleomycin—lymphatic system cancer	9.08e-05	0.0029	CcSEcCtD
Pralatrexate—Asthenia—Carmustine—lymphatic system cancer	9.03e-05	0.00288	CcSEcCtD
Pralatrexate—Epistaxis—Methotrexate—lymphatic system cancer	8.62e-05	0.00275	CcSEcCtD
Pralatrexate—Asthenia—Vincristine—lymphatic system cancer	8.62e-05	0.00275	CcSEcCtD
Pralatrexate—Diarrhoea—Carmustine—lymphatic system cancer	8.61e-05	0.00275	CcSEcCtD
Pralatrexate—Nausea—Bleomycin—lymphatic system cancer	8.56e-05	0.00274	CcSEcCtD
Pralatrexate—Asthenia—Mitoxantrone—lymphatic system cancer	8.39e-05	0.00268	CcSEcCtD
Pralatrexate—Diarrhoea—Vincristine—lymphatic system cancer	8.22e-05	0.00263	CcSEcCtD
Pralatrexate—Diarrhoea—Mitoxantrone—lymphatic system cancer	8e-05	0.00256	CcSEcCtD
Pralatrexate—Vomiting—Carmustine—lymphatic system cancer	8e-05	0.00256	CcSEcCtD
Pralatrexate—Rash—Carmustine—lymphatic system cancer	7.93e-05	0.00253	CcSEcCtD
Pralatrexate—Dermatitis—Carmustine—lymphatic system cancer	7.93e-05	0.00253	CcSEcCtD
Pralatrexate—Vomiting—Vincristine—lymphatic system cancer	7.64e-05	0.00244	CcSEcCtD
Pralatrexate—Rash—Vincristine—lymphatic system cancer	7.57e-05	0.00242	CcSEcCtD
Pralatrexate—Dermatitis—Vincristine—lymphatic system cancer	7.57e-05	0.00242	CcSEcCtD
Pralatrexate—Nausea—Carmustine—lymphatic system cancer	7.47e-05	0.00239	CcSEcCtD
Pralatrexate—Vomiting—Mitoxantrone—lymphatic system cancer	7.44e-05	0.00238	CcSEcCtD
Pralatrexate—Rash—Mitoxantrone—lymphatic system cancer	7.37e-05	0.00236	CcSEcCtD
Pralatrexate—Dermatitis—Mitoxantrone—lymphatic system cancer	7.37e-05	0.00235	CcSEcCtD
Pralatrexate—Nausea—Vincristine—lymphatic system cancer	7.13e-05	0.00228	CcSEcCtD
Pralatrexate—Nausea—Mitoxantrone—lymphatic system cancer	6.95e-05	0.00222	CcSEcCtD
Pralatrexate—Back pain—Methotrexate—lymphatic system cancer	6.91e-05	0.00221	CcSEcCtD
Pralatrexate—Anaemia—Methotrexate—lymphatic system cancer	6.6e-05	0.00211	CcSEcCtD
Pralatrexate—Leukopenia—Methotrexate—lymphatic system cancer	6.39e-05	0.00204	CcSEcCtD
Pralatrexate—Cough—Methotrexate—lymphatic system cancer	6.23e-05	0.00199	CcSEcCtD
Pralatrexate—Thrombocytopenia—Methotrexate—lymphatic system cancer	5.71e-05	0.00182	CcSEcCtD
Pralatrexate—Anorexia—Methotrexate—lymphatic system cancer	5.55e-05	0.00177	CcSEcCtD
Pralatrexate—Dyspnoea—Methotrexate—lymphatic system cancer	5.2e-05	0.00166	CcSEcCtD
Pralatrexate—Decreased appetite—Methotrexate—lymphatic system cancer	5.07e-05	0.00162	CcSEcCtD
Pralatrexate—Fatigue—Methotrexate—lymphatic system cancer	5.02e-05	0.00161	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Methotrexate—lymphatic system cancer	4.77e-05	0.00152	CcSEcCtD
Pralatrexate—Abdominal pain—Methotrexate—lymphatic system cancer	4.61e-05	0.00147	CcSEcCtD
Pralatrexate—Body temperature increased—Methotrexate—lymphatic system cancer	4.61e-05	0.00147	CcSEcCtD
Pralatrexate—Asthenia—Methotrexate—lymphatic system cancer	4.18e-05	0.00134	CcSEcCtD
Pralatrexate—Pruritus—Methotrexate—lymphatic system cancer	4.12e-05	0.00132	CcSEcCtD
Pralatrexate—Diarrhoea—Methotrexate—lymphatic system cancer	3.99e-05	0.00127	CcSEcCtD
Pralatrexate—Vomiting—Methotrexate—lymphatic system cancer	3.71e-05	0.00118	CcSEcCtD
Pralatrexate—Rash—Methotrexate—lymphatic system cancer	3.67e-05	0.00117	CcSEcCtD
Pralatrexate—Dermatitis—Methotrexate—lymphatic system cancer	3.67e-05	0.00117	CcSEcCtD
Pralatrexate—Nausea—Methotrexate—lymphatic system cancer	3.46e-05	0.00111	CcSEcCtD
